Teva Pharmaceutical Industries (NYSE:TEVA)

Major Pharma Short Sellers Couldn’t Make Up Their Minds Before Failed Trump Health Care Vote

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Back Off Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
thumbs up and down

Top Analyst Upgrades and Downgrades: Apple, CVS Health, Priceline, Teva Pharmaceuticals, Workday and Many More

The Dow Jones Industrial Average posted a 12th consecutive gain yesterday matching a record set way back in 1987. This morning the futures are looking slightly down, as investors try ...
Read Full Story »
Prescription drugs

Why Short Sellers Are Making a Massive Bet in Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
thumbs up and down

What Analysts Are Saying About Teva Pharmaceutical After Earnings

Teva Pharmaceutical International Inc. (NYSE: TEVA) reported fourth-quarter and full-year 2016 results before markets opened Monday. Only a few analysts weighed in initially, but the consensus is slowly growing more ...
Read Full Story »
analysis

Top Analyst Upgrades and Downgrades: Intuitive Surgical, Restaurant Brands, Scorpio Tankers, Teva, Under Armour, Zillow and Many More

Stocks were simply looking for direction on Tuesday, ahead of the wholesale inflation report and ahead of Fed Chair Yellen's testimony. Regardless of the day's final move, the Dow has ...
Read Full Story »
Medicine pills

How Rosy Is the Outlook for Teva Pharmaceutical?

Teva Pharmaceutical International Inc. (NYSE: TEVA) reported fourth-quarter and full-year 2016 results before markets opened Monday. The company reported quarterly adjusted diluted earnings per share (EPS) of $1.38 and revenues ...
Read Full Story »
ThinkstockPhotos-475180302

Top 7 Earnings to Look For This Week

24/7 Wall St. has put together a preview of some of the most anticipated quarterly earnings reports expected this coming week. Although earnings season is practically over, the broad markets ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Ford, Intel, NVIDIA, Starbucks, Teva, Twitter, Wal-Mart and Many More

Stocks were indicated marginally higher on Friday morning on what seems to be a very light news day. The Dow is still above 20,000 and the S&P 500 has gone ...
Read Full Story »
Pair of dice

Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
Stock Price

Gilead Sciences, Fitbit Plunge into Wednesday’s 52-Week Low Club

February 8, 2017: Here are four stocks trading with relatively heavy volume among 69 equities making new 52-week lows in Wednesday's session. On the NYSE, advancers led decliners by less than ...
Read Full Story »
Stock Price

Teva, Kors Stagger into Tuesday’s 52-Week Low Club

February 7, 2017: Here are four stocks trading with relatively heavy volume among 58 equities making new 52-week lows in Tuesday's session. On the NYSE, decliners led advancers by about 8 ...
Read Full Story »
Pills and tablets

Is Teva’s CEO Departure Long Overdue?

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) saw its shares tumble on Tuesday after the company announced a changing of the guard for its CEO position. The company reported that Dr. ...
Read Full Story »
Female patient on gurney

Why Analysts Are Chasing Momenta Pharmaceuticals Even Higher

Shares of Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) made a huge gain on Tuesday after the company reported a key legal decision in its favor. Essentially, the U.S. District Court for the ...
Read Full Story »
bull and bear

2 Key Analysts Strongly Defend Teva After Copaxone Patent Ruling Loss

When pharmaceutical companies lose patent cases on the blockbuster drugs, it usually means that they are at risk of losing billions of dollars in drug sales. When Teva Pharmaceutical Industries ...
Read Full Story »